Journal of pharmacy practice最新文献

{"title":"Clevidipine for Nicardipine Resistant Hypertension in Neurocritically Ill Patients.","authors":"J Tyler Haller, Christian Eslinger, Nicholas Nelson, Anusha Mangalampalli, Aditya Kumar, Chia-Ling Phuah, Lindsey Stubbs, Abigail Tittle, Sarah Sternbach, Diane McLaughlin","doi":"10.1177/08971900261483494","DOIUrl":"https://doi.org/10.1177/08971900261483494","url":null,"abstract":"<p><p>Acute hypertension is common in acute brain injuries and contributes to increased morbidity and mortality. The optimal agent to manage acute hypertension is unclear, though most critically ill patients in the Neuro Intensive Care Unit (Neuro ICU) are managed with nicardipine as a first line agent. If hypertension is inadequately controlled despite the maximal dose of nicardipine, few other agents exist that are both safe and efficacious. Clevidipine may be an optimal agent for nicardipine refractory hypertension. This retrospective cohort study included acute brain injured patients that were unable to achieve blood pressure goals despite maximal doses of nicardipine and were switched to clevidipine. The primary outcome was to evaluate the percentage of patients that achieved systolic blood pressure goals within 1 hour of clevidipine initiation. Secondary outcomes included hypotension, need for vasopressors, and development of tachycardia. Additional outcomes included duration of antihypertensive infusions and administration of as-needed hypertension medications. Out of 410 screened patients, 66 were included (median age 53.7 years, 43.9% female). Patients were at maximum nicardipine dose (15 mg/hr) when clevidipine was initiated in 91% of cases. Among those included, 77.3% of patients were unable to achieve goal blood pressure while on nicardipine therapy. Goal blood pressure was able to be achieved within 1 hour in 84.8% of patients receiving clevidipine. Adverse effects were minimal, with only 4 (6%) patients experiencing hypotension and 4 (6%) patients developing tachycardia within 12hrs of clevidipine initiation. The median duration of clevidipine infusion was 23.9 hours. Clevidipine appears to be an effective, safe alternative agent in patients that are unable to achieve blood pressure goals with nicardipine infusion. Future prospective, multicenter studies are needed to validate these findings and assess long-term neurological outcomes. Clinicians managing nicardipine-refractory hypertension in neurocritically ill patients may consider clevidipine as a structured second-line option pending such evidence.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261483494"},"PeriodicalIF":1.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps Between Intended Learning and Practice in PGY1 Pharmacy Residency Programs: Alignment of Training Experiences With Accreditation Standards.","authors":"Sharmon P Osae, Daniel B Chastain","doi":"10.1177/08971900261480294","DOIUrl":"https://doi.org/10.1177/08971900261480294","url":null,"abstract":"<p><p>Postgraduate Year One (PGY1) pharmacy residency programs are critical for developing clinically advanced pharmacists equipped with the skills necessary to improve patient care. However, alignment between intended training experiences, accreditation standards, and real-world implementation remains variable. Competency development in research and interprofessional collaboration may be compromised by operational demands such as central staffing or inconsistent communication practices. A 2020 multisite survey of University of Georgia-affiliated PGY1 programs revealed that while research time was universally allotted, 50% of residents reported being reassigned to other responsibilities during this period. Additionally, less than half of preceptors noted that pulling residents for staffing negatively impacted rotation goals. Discrepancies were also identified in perceptions of interprofessional communication. These findings support the need for intentional program design that protects educational integrity, ensures competency development, and prepares residents to meet the demands of modern pharmacy practice.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261480294"},"PeriodicalIF":1.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing Post-Residency Career Choices Among Graduating PGY1 Pharmacy Residents.","authors":"Marcus Mize, Carrie N Baker, Riley D Bowers","doi":"10.1177/08971900261477880","DOIUrl":"https://doi.org/10.1177/08971900261477880","url":null,"abstract":"<p><p><b>Purpose:</b> To examine factors that influence the post-residency decision-making process of PGY1 pharmacy residents. <b>Methods:</b> An eleven-question survey was disseminated to individuals who completed a PGY1 residency in the past 5 years (2019-2023). The primary outcome was the most common factors that influenced PGY1 residents to choose either a PGY2 residency or employment after graduation. Factors evaluated included finances, family obligations, clinical experience, burnout, and career opportunities. Only fully completed surveys were included in analyses. <b>Results:</b> A total of 135 participants completed the survey. Response rate from all possible PGY1 graduates was 1.3%, with a response rate of 50.6% of those who clicked the distributed survey link. Of the 135 responses, 89 (66%) pursued PGY2 residency, while 46 (34%) pursued employment. Of those pursuing PGY2, desire to specialize, clinical experience, and career opportunities were the top 3 factors influencing their decision. Those choosing employment reported well-being/burnout, career opportunities, and job outlook as their top 3 most influential factors. Statistically significant differences were observed regarding the influence of 7 (64%) factors contributing to deciding between pursuing a PGY2 residency or employment, although some, including convenience and competitiveness of a specialty, had low scores on overall influence. <b>Conclusion:</b> Many factors influence post-PGY1 career decision with desire to specialize being the most influential factor among those pursuing PGY2, while well-being/burnout was the most influential factor among those pursuing employment. By identifying these factors, the study contributes to a deeper understanding of resident preferences and informs strategies to optimize pharmacy education and training programs.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261477880"},"PeriodicalIF":1.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Direct Oral Anticoagulants Treatment Failure for Venous Thromboembolism in the Setting of Multiple Thrombophilic Conditions.","authors":"Dominick Panzera, Evan Sasson","doi":"10.1177/08971900261479657","DOIUrl":"https://doi.org/10.1177/08971900261479657","url":null,"abstract":"<p><p>This case report describes the treatment failure of two direct oral anticoagulants (DOACs) in a patient with multiple thrombophilic conditions, including triple-positive antiphospholipid syndrome (APS) and heterozygous Factor V Leiden mutation. A 69-year-old male with a history of recurrent venous thromboembolism developed a deep vein thrombosis while receiving rivaroxaban, followed by an acute ischemic stroke while on dabigatran. Due to recurrent thrombosis despite therapeutic DOAC therapy, the patient was transitioned to warfarin with low-molecular-weight heparin bridging. After achieving a therapeutic INR, the patient remained stable without further thromboembolic or bleeding events during follow-up in a pharmacist-managed anticoagulation clinic.Current guidelines, including the 2020 ISTH Scientific and Standardization Committee guidance, recommend vitamin K antagonists over DOACs in high-risk APS, particularly in patients with triple-positive antibodies, due to the increased risk of recurrent thrombosis with DOAC therapy. This recommendation is supported by the TRAPS trial, which demonstrated a significantly higher rate of thromboembolic events with rivaroxaban compared to warfarin in triple-positive APS patients.This case supports existing guideline recommendations and highlights the limitations of targeted anticoagulation, including both factor Xa inhibitors and direct thrombin inhibitors, in patients with complex thrombophilia. In patients with high-risk APS or multiple thrombophilic conditions, warfarin has been shown to be more reliable anticoagulation compared with DOACs. The sequential failure of two mechanistically distinct DOACs in this case further underscores the importance of guideline-concordant anticoagulant selection and the role of pharmacists in identifying high-risk patients at the point of prescribing and dispensing.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261479657"},"PeriodicalIF":1.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized Bone Health Assessment and Treatment Among Prostate Cancer Patients on Androgen Deprivation Therapy in a Large Integrated Managed Care Delivery System.","authors":"Michael J Shulman, Brandon H Horton, Joan C Lo, Marilyn J Meganck, Masy K Miller, Jennifer J Park-Sigal, Andrew L Avins","doi":"10.1177/08971900261478840","DOIUrl":"https://doi.org/10.1177/08971900261478840","url":null,"abstract":"<p><p><b>Background:</b> Bone-health risk assessment and treatment among prostate-cancer patients on androgen-deprivation therapy (ADT) is often inadequately completed in clinical practice. <b>Objective:</b> To determine the impact of a population-management program on bone-health risk assessment and bisphosphonate therapy among prostate-cancer patients on ADT. <b>Methods:</b> We used retrospective data from a large integrated healthcare system to identify men aged 41-89 years diagnosed with prostate cancer in 2011-2024 who received ≥1 ADT dose. We compared adherence to internal guideline-recommended bone mineral density (BMD) testing, laboratory evaluation, and bisphosphonate prescriptions at baseline and during follow-up between men enrolled in the population-health program with men and men who were not enrolled (non-enrolled). <b>Results:</b> Among the 9934 eligible patients, 1680 (17%) were enrolled in the program and 8254 (83%) were non-enrolled. The proportion of enrolled patients completing BMD scans within 1 year before or after ADT initiation (80.6%) was substantially higher than among non-enrolled patients (23.8%, <i>P</i> < 0.0001). More enrolled patients were treated with antiresorptive therapy (26.4%) than among non-enrolled patients (14.1%, <i>P</i> < 0.0001). Overall, enrollees were more likely to have ever received any guideline-indicated intervention (78.7% vs 27.8%, <i>P</i> < 0.0001). The average coverage percentage for BMD screening was 24.4% among non-enrolled patients vs 81.1% among enrolled patients (<i>P</i> < 0.0001). Among antiresorptive-treatment-eligible patients, the average coverage percentage for bisphosphonate therapy was 35.5% among non-enrolled patients compared with 46.1% among enrolled patients (<i>P</i> < 0.0001). <b>Conclusion:</b> The population-management program significantly outperformed usual care in adherence to BMD testing, laboratory evaluation, and indicated antiresorptive osteoporosis-medication treatment among men with prostate cancer on ADT.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261478840"},"PeriodicalIF":1.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time and Workflow Burden Associated With Manual Monitoring of Automated Dispensing Cabinet Overrides.","authors":"Jacqueline Pham, Wyndie Tse, Tiffany Nguyen, Craig A Greszler, Heather D Nelkin","doi":"10.1177/08971900261478841","DOIUrl":"https://doi.org/10.1177/08971900261478841","url":null,"abstract":"<p><p>Automated dispensing cabinet (ADC) overrides facilitate timely medication access but bypass standard medication-use safety checks, necessitating ongoing monitoring to identify potential risks. Many health systems rely on manual, retrospective workflows to review override activity, yet operational burden associated with these processes is not well characterized. Objectives of the evaluation were to describe the workflow, quantify the time burden, and identify limitations associated with a manual ADC override monitoring process within a large health system. This retrospective, descriptive quality improvement evaluation was conducted at a large oncology-focused health system. The existing ADC override review process was assessed over a 6-month period. Workflow steps included generation of external reports, manual alignment and manipulation of data within spreadsheets, and creation of pivot table summaries for analysis across patient care areas. Time required to complete each monthly override audit was tracked, and process limitations were documented. The mean time required to complete a monthly override audit was 1 h and 7 min, with a range of 42 min to 1 h and 55 min. The most time-intensive activities were spreadsheet construction, data manipulation, and report preparation. Additional effort was required to train and validate reviewers. Key process limitations included reliance on retrospective reporting, lack of standardized review methodologies, and challenges aggregating data to identify system-level trends. Manual ADC override monitoring is resource intensive and subject to variability due to retrospective, spreadsheet-based workflows. These findings suggest a need for optimized and standardized approaches to support medication safety surveillance and improve scalability of override review processes.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261478841"},"PeriodicalIF":1.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradoxical Agitation Following Etomidate Sedation for Electrical Cardioversion: A Case Report.","authors":"Madeline Palmer, Emma L Chee-How, Callie O'Bryant, Emily Grass","doi":"10.1177/08971900261477883","DOIUrl":"https://doi.org/10.1177/08971900261477883","url":null,"abstract":"<p><p>Etomidate is commonly used for procedural sedation in the emergency department due to its rapid onset, short duration of action, and favorable hemodynamic profile. Adverse effects are generally limited to pain at the injection site, myoclonus, nausea, and transient adrenal suppression. Paradoxical agitation following etomidate administration is rarely described. We report a case of severe, transient agitation following low-dose etomidate used for procedural sedation to facilitate electrical cardioversion in a healthy young adult presenting with new-onset atrial fibrillation.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261477883"},"PeriodicalIF":1.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of Pre-operative P2Y12 Levels for Perioperative Bleeding Risk in Isolated Coronary Artery Bypass Surgery.","authors":"Crystal Li, Joshua L Leibowitz, Justin Robinson, Stephen Stachnik, Alison Grazioli, Douglas Anderson, Michael E Plazak, Reney A Henderson, Bradley S Taylor, Aakash Shah","doi":"10.1177/08971900261477838","DOIUrl":"https://doi.org/10.1177/08971900261477838","url":null,"abstract":"<p><p>A retrospective review of patients at a single institution who underwent isolated coronary artery bypass (CABG) surgery between 2017 and 2023 was conducted to investigate the clinical utility of pre-operatively measuring platelet inhibition as a predictor of bleeding complications, especially in the context of bypass surgery. Patients who underwent CABG procedure and were on P2Y12 inhibitors such as clopidogrel or ticagrelor preoperatively and had preoperative P2Y12 platelet reactivity unit (PRU) level measured. Patients were stratified by a PRU <200 or ≥200. In both groups, patients were divided into patients who took clopidogrel and patients who took ticagrelor. There were 189 patients included in the study. Patients with a PRU ≥200 were of similar age and comorbidities to those with a PRU <200, however, more were female. Both groups had a similar mean duration of days since last P2Y12 inhibitor dose prior to surgery. There were greater intraoperative platelet transfusions in the PRU <200 group (mean 0.7 vs 0.3 units, <i>P</i> = 0.001). Intraoperative red blood cell and plasma transfusion and postoperative transfusions, 24-hour chest tube output, and re-exploration for bleeding were similar between the groups. There were no differences in bleeding complications between pharmacologic agent in either group. Our findings suggest that preoperative assessment of P2Y12 PRU may have limited clinical utility at a cutoff of 200 in predicting bleeding in patients undergoing CABG. Patients with PRU <200 received higher rates of platelet transfusion, without differences in other blood products.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261477838"},"PeriodicalIF":1.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Sequential Nephron Blockade Compared to Standard Loop Diuretic for Fluid De-resuscitation in the ICU.","authors":"Noelle Brittain, Megan Van Berkel Patel, Lauren Caldwell, Andrew Shine, Jeremy Greenberg, Jessica Parker, Nolan Rossman, Jessica Briscoe","doi":"10.1177/08971900261477835","DOIUrl":"https://doi.org/10.1177/08971900261477835","url":null,"abstract":"<p><p>Diuretics are integral in fluid de-resuscitation of ICU patients following initial stabilization. While loop diuretics are commonly used, sequential nephron blockade (SNB) is an alternative diuretic strategy that combines a loop diuretic with at least one diuretic from another pharmacologic class to increase efficacy and limit adverse effects. The objective of this study was to compare the safety and efficacy of SNB to loop diuretics alone for de-resuscitation of critically ill patients. This retrospective study included adult ICU patients who received either a loop diuretic alone or combined with an aldosterone antagonist, carbonic anhydrase inhibitor, and/or thiazide diuretic on two consecutive days. The primary outcome was comparison of diuretic efficacy, assessed by urine output, on diuresis day 1. Secondary outcomes included comparison of diuretic efficacy on diuresis days 2-5 and incidence of acute kidney injury and electrolyte abnormalities on diuresis day 1. A total of 100 patients were included (SNB = 15, Loop = 85). At baseline, SNB patients had more hypernatremia (20% vs 2.4%, <i>P</i> = 0.023) and hyperchloremia (20% vs 2.4%, <i>P</i> = 0.023). Patients in the SNB group had increased urine output on diuresis day 1 (4725 vs 2215 mL, <i>P</i> = 0.0004). AKI did not occur in SNB patients on diuresis day 1 vs 15.5% of loop patients (<i>P</i> = 0.208). Hypernatremia (26.7% vs 2.4%, <i>P</i> = 0.004) and hyperchloremia (13.3% vs 3.5%, <i>P</i> = 0.161), persisted in the SNB group on diuretic day 2. In conclusion, among ICU patients requiring de-resuscitation, SNB may be associated with improved diuresis and similar safety concerns compared to loop diuretics alone.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261477835"},"PeriodicalIF":1.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS).","authors":"Ilaria Mariani, Giulia Mosini, Stefania Cheli, Sofia Dinegro, Andrea Vicenzi, Cecilia Bonino, Vera Battini, Carla Carnovale, Emilio Clementi, Sonia Radice","doi":"10.1177/08971900251376797","DOIUrl":"10.1177/08971900251376797","url":null,"abstract":"<p><p>Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 - 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 - 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"342-347"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}